CN105263475A - 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药 - Google Patents

雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药 Download PDF

Info

Publication number
CN105263475A
CN105263475A CN201480015321.7A CN201480015321A CN105263475A CN 105263475 A CN105263475 A CN 105263475A CN 201480015321 A CN201480015321 A CN 201480015321A CN 105263475 A CN105263475 A CN 105263475A
Authority
CN
China
Prior art keywords
triptolide
weight
oil
sodium
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015321.7A
Other languages
English (en)
Chinese (zh)
Inventor
安金华
何卫国
约翰·M·费德勒
约翰·H·马瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MYELORX LLC
Pharmagenesis Inc
Original Assignee
MYELORX LLC
Pharmagenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MYELORX LLC, Pharmagenesis Inc filed Critical MYELORX LLC
Publication of CN105263475A publication Critical patent/CN105263475A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480015321.7A 2013-03-15 2014-03-15 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药 Pending CN105263475A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794926P 2013-03-15 2013-03-15
US61/794,926 2013-03-15
PCT/US2014/030041 WO2014145303A1 (en) 2013-03-15 2014-03-15 Intravenous emulsions of triptolide as immunomodulators and anticancer agents i

Publications (1)

Publication Number Publication Date
CN105263475A true CN105263475A (zh) 2016-01-20

Family

ID=51537944

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015321.7A Pending CN105263475A (zh) 2013-03-15 2014-03-15 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药

Country Status (7)

Country Link
US (1) US20160038454A1 (enExample)
EP (1) EP2968140A4 (enExample)
JP (1) JP2016515530A (enExample)
CN (1) CN105263475A (enExample)
HK (1) HK1219228A1 (enExample)
TW (1) TWI597071B (enExample)
WO (1) WO2014145303A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106946975A (zh) * 2017-03-16 2017-07-14 上海天氏利医药科技有限公司 一种雷公藤甲素衍生物及其制备方法与制剂
CN106994129A (zh) * 2017-05-15 2017-08-01 王晓辉 雷公藤甲素及其衍生物在制备治疗和/或预防肺损伤疾病的药物中的应用
CN107663225A (zh) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 一种氟代雷公藤内酯醇内酯环衍生物
CN109771430A (zh) * 2019-03-15 2019-05-21 大连大学 甘氨胆酸在制备抗肿瘤药物中的应用
CN111494319A (zh) * 2020-06-15 2020-08-07 沈阳药科大学 雷公藤甲素复方组合物及其制备方法与应用
WO2022258035A1 (zh) * 2021-06-11 2022-12-15 复旦大学 一种胆碱碳酸酯类前药及其制备方法和应用
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881878T3 (es) * 2015-09-11 2021-11-30 Ys Ac Co Ltd Composición para el tratamiento del cáncer que combina el anticuerpo anti-CD26 y otro antineoplásico
US10342797B2 (en) 2016-03-13 2019-07-09 LivePet, LLC Solubility of therapeutic agents
CN108530511B (zh) * 2017-03-02 2021-06-22 欣凯医药化工中间体（上海）有限公司 一种c19-酰基化雷公藤甲素衍生物
WO2018222351A1 (en) * 2017-05-27 2018-12-06 Pharmagenesis, Inc. Triptolide lactone derivatives as immunomodulators and anticancer agents
WO2019173526A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN114569554A (zh) * 2022-03-01 2022-06-03 福建省医学科学研究院 一种肿瘤靶向性雷公藤内酯醇乳液及其制备方法
CN114831962A (zh) * 2022-04-29 2022-08-02 福建省医学科学研究院 一种雷公藤内酯醇固体脂质纳米粒及其滴丸的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084365A2 (en) * 2004-03-02 2005-09-15 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
CN1726025A (zh) * 2002-12-17 2006-01-25 泛华医药公司 作为免疫调节剂和抗癌剂的雷公藤内酯醇衍生物
CN102552137A (zh) * 2012-02-22 2012-07-11 福建医科大学 雷公藤内酯醇脂肪乳注射剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3631795A (en) * 1994-09-15 1996-03-29 Pharmagenesis, Inc. Composition and method for immunotherapy
AP2626A (en) * 2005-08-29 2013-03-26 Sepsicure Llc Method for treatment or prevention of conditions caused by gram-positive bacteria
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
CN102793674B (zh) * 2011-05-26 2014-11-26 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726025A (zh) * 2002-12-17 2006-01-25 泛华医药公司 作为免疫调节剂和抗癌剂的雷公藤内酯醇衍生物
WO2005084365A2 (en) * 2004-03-02 2005-09-15 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
CN102552137A (zh) * 2012-02-22 2012-07-11 福建医科大学 雷公藤内酯醇脂肪乳注射剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
傅超美，等: "《药用辅料学》", 31 October 2008 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107663225A (zh) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 一种氟代雷公藤内酯醇内酯环衍生物
CN106946975A (zh) * 2017-03-16 2017-07-14 上海天氏利医药科技有限公司 一种雷公藤甲素衍生物及其制备方法与制剂
CN106994129A (zh) * 2017-05-15 2017-08-01 王晓辉 雷公藤甲素及其衍生物在制备治疗和/或预防肺损伤疾病的药物中的应用
CN109771430A (zh) * 2019-03-15 2019-05-21 大连大学 甘氨胆酸在制备抗肿瘤药物中的应用
CN111494319A (zh) * 2020-06-15 2020-08-07 沈阳药科大学 雷公藤甲素复方组合物及其制备方法与应用
WO2022258035A1 (zh) * 2021-06-11 2022-12-15 复旦大学 一种胆碱碳酸酯类前药及其制备方法和应用
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法

Also Published As

Publication number Publication date
WO2014145303A1 (en) 2014-09-18
HK1219228A1 (zh) 2017-03-31
US20160038454A1 (en) 2016-02-11
EP2968140A4 (en) 2016-11-16
TW201440812A (zh) 2014-11-01
JP2016515530A (ja) 2016-05-30
EP2968140A1 (en) 2016-01-20
TWI597071B (zh) 2017-09-01

Similar Documents

Publication Publication Date Title
CN105263475A (zh) 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药
JP4267697B2 (ja) 免疫抑制性化合物および方法
KR102500181B1 (ko) 암-표적화 약물 운송수단으로서의 인지질 에테르 유사체
JP5057966B2 (ja) 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
JP2020503289A (ja) Ｈｓｐ９０標的化コンジュゲート及びその製剤
JP4680589B2 (ja) アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
CA3130349A1 (en) Lipid prodrugs of jak inhibitors and uses thereof
CN101420963A (zh) 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物
JP2011525486A (ja) 活動亢進性免疫系を治療するためのシクロリグナンの使用
US6548537B1 (en) Triptolide prodrugs having high aqueous solubility
KR20180112060A (ko) Hsp90 표적화된 접합체 및 이의 입자 및 제형
CN113150030A (zh) 氧杂二环庚烷前药
US7098348B2 (en) Triptolide derivatives as immunomodulators and anticancer agents
CN1483731A (zh) 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
EP4587449A1 (en) Amino acid and carbohydrate psilocin derivatives
CN105777769B (zh) 一种7-乙基-10-羟基喜树碱的衍生物及其制备方法与应用
JP5653939B2 (ja) 抗癌剤および免疫調節因子としてのトリプトリドｃ環誘導体
CN108699060A (zh) 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途
JP2004525136A (ja) イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用
BR112019013493A2 (pt) Compostos heterocíclicos e seus usos
JPH05500811A (ja) アンタマニド含有薬
JP2013527228A (ja) 新規な医薬化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219228

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20160120

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219228

Country of ref document: HK